Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Approval For DVT Bodes Well For Coming Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's July 1 approval of Johnson & Johnson's oral anticoagulant comes after a long review process, and in front of some key decision points that will shape the rivaroxaban program's future.
Advertisement

Related Content

ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle
Xarelto Expanded Indication May Depend On Containing Worries About Bleeding
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
Xarelto's Efficacy Impresses In ACS, But Bleeding Risk Will Complicate Approval
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors

Topics

Advertisement
UsernamePublicRestriction

Register

PS072595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel